Brief: Ipsen Obtains Exclusive Worldwide Rights To Develop And Commercialise Mesdopetam

IRLAB Therapeutics AB

15/07/2021 17:32

July 15 (Reuters) - IPSEN SA  IPN.PA :
    * IPSEN SA AND IRLAB ENTER EXCLUSIVE WORLDWIDE LICENSING
AGREEMENT
AIMED TO IMPROVE LIVES OF PEOPLE LIVING WITH PARKINSON'S DISEASE
    * OBTAINS EXCLUSIVE WORLDWIDE RIGHTS TO DEVELOP AND
COMMERCIALIZE
INVESTIGATIONAL TREATMENT MESDOPETAM
    * AGREEMENT TO COMMERCIALIZE INVESTIGATIONAL TREATMENT
MESDOPETAM
WHICH IS BASED ON A NOVEL MECHANISM OF ACTION
    * UNDER THE TERMS OF THE AGREEMENT, IRLAB WILL BE ELIGIBLE
TO
RECEIVE UP TO $363M, INCLUDING AN UPFRONT CASH PAYMENT OF $28M
AND UP TO $335M IN DEVELOPMENT, REGULATORY AND COMMERCIAL
MILESTONES
    * THE TRANSACTION DOES NOT IMPACT IPSEN’S FINANCIAL GUIDANCE
FOR
2021
    * IRLAB WILL CONTINUE TO BE RESPONSIBLE FOR ONGOING PHASE
IIB
TRIAL

Source text for Eikon:  ID:nNDL3KNQVr 
Further company coverage:  IPN.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))